A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma

Analysis of the Tumor Microenvironment and Immune Response in Malignant Melanoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04567706

Enrollment

1000

Registered

2020-09-28

Start date

2013-05-07

Completion date

2027-10-31

Last updated

2026-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma

Brief summary

This study collects and stores blood and tumor samples from patients with malignant melanoma and healthy individuals. The purpose of this study is to gain a better understanding of the causes of melanoma and how melanoma tumors behave. Storing blood and tumor samples for future research may lead to new discoveries that may ultimately help with diagnosing or treating this disease.

Detailed description

PRIMARY OBJECTIVE: I. Facilitate studies aimed at investigating new prognostic markers and potentially therapeutic therapies in malignant melanoma. OUTLINE: Patients undergo collection of blood samples at the time of the initial diagnostic work-up, and possibly prior to the initiation of surgery, chemotherapy, immunotherapy, or radiation therapy, at tumor progression or recurrence, and annually during routine follow-up (no more than 4 blood draws per year). Patients may also undergo collection of tissue sample during standard of care surgical or radiologic procedures. Healthy individuals undergo collection of blood samples up to 4 times over 1 year.

Interventions

PROCEDUREBiospecimen Collection

Undergo collection of blood and tissue samples

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Patient with malignant melanoma or personal history of melanoma * Normal donors * Informed consent can be obtained * Patients with any stage of malignant melanoma

Exclusion criteria

* Incarcerated individuals will be excluded from this protocol

Design outcomes

Primary

Measure	Time frame	Description
New prognostic markers in malignant melanoma	Up to 3 months	Facilitate studies aimed at investigating new prognostic markers and potentially therapeutic therapies in malignant melanoma. . Draws conducted at baseline prior to immune therapy, four weeks after draw 1 and prior to the third cycle.

Countries

United States

Contacts

CONTACTThe Ohio State University Comprehensive Cancer Center

OSUCCCClinicaltrials@osumc.edu800-293-5066

PRINCIPAL_INVESTIGATORWilliam E Carson, MD

Ohio State University Comprehensive Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026